Long‐term Combination of Interferon Alfa‐2b and Ribavirin for Hepatitis C Recurrence in Liver Transplant Patients
Long‐term Combination of Interferon Alfa‐2b and Ribavirin for Hepatitis C Recurrence in Liver Transplant Patients
复制标题
干扰素 Alfa-2b 和利巴韦林长期联合治疗肝移植患者丙型肝炎复发
DOI：
--
复制
发表时间：
2001
影响因子：
8.8
通讯作者：
J. Scheele
中科院分区：
文献类型：
--
作者：
A. Kornberg;M. Hommann;A. Tannapfel;T. Wagner;T. Grube;U. Schotte;R. Voigt;J. Scheele
本研究的目的是评估干扰素α-2b（IFNα-2b）和利巴韦林（Rb）长期联合治疗肝移植术后复发性丙型肝炎的可行性、耐受性和疗效。对15例肝移植术后经组织学证实的丙型肝炎患者进行了治疗。经过12个月的基础疗程（IFNα-2b 3 MU/每周3次; Rb 3 × 200 mg/天）后，达到病毒血症清除的患者接受利巴韦林（3 × 200 mg/天）维持治疗。 无病毒学应答的患者继续接受联合治疗。随访HCV RNA、转氨酶和胆红素水平。所有患者治疗后转氨酶和胆红素均显著下降（p <0.05）。 64%的患者在12个月后清除了病毒血症。 持续病毒学应答率为88%。在无病毒学应答的患者中，继续联合治疗可预防肝炎的另一次生化复发。治疗伴随着严重的血液学副作用，大多数患者需要医疗支持。在2例患者（13.5%）中，由于严重血液学疾病最终不得不停止治疗。这些结果表明，IFNα-2b和Rb的长期联合治疗可有效治疗复发性丙型肝炎，并可预防肝移植后疾病的进一步复发，但副作用可能需要停止治疗。
The purpose of this study was to evaluate the feasibility, tolerability and efficacy of long‐term combination therapy with interferon‐alfa 2b (IFNα‐2b) and ribavirin (Rb) for recurrent hepatitis C after liver transplantation. Fifteen patients with histologically confirmed hepatitis C after liver transplantation were treated. After a basic course of 12 months (IFNα‐2b 3 MU/3 times a week; Rb 3 × 200 mg/day), patients achieving clearance of viremia underwent maintenance therapy with ribavirin (3 × 200 mg/day). Patients without virological response continuously received combination therapy. Levels of HCV RNA, aminotransferases and bilirubin were followed. Therapy led to a significant decline of transaminases and bilirubin in all patients (p < 0.05). Sixty‐four per cent of patients had clearance of viremia after 12 months. Sustained virological response was 88%. In patients without virological response, continuation of combination therapy prevented another biochemical relapse of hepatitis. Treatment was accompanied by severe hematological side‐effects, requiring medical support in a majority of patients. In two patients (13.5%), therapy finally had to be withdrawn because of major hematological disorders. These results indicate that long‐term combination therapy with IFNα‐2b and Rb is effective in the treatment of recurrent hepatitis C and in preventing further relapse of disease after liver transplantation, but side‐effects may require cessation of therapy.
影响因子：
158.5
作者：
McHutchison, JG;Gordon, SC;Albrecht, JK
通讯作者：
Albrecht, JK
利巴韦林的分子作用机制。
DOI：
10.1093/clinids/12.6.1139
发表时间：
1990
期刊：
Reviews of infectious diseases
影响因子：
--
作者：
Patterson,JL;Fernandez-Larsson,R
通讯作者：
Fernandez-Larsson,R